image
Healthcare - Medical - Devices - NASDAQ - US
$ 18.08
2.73 %
$ 691 M
Market Cap
-5.76
P/E
1. INTRINSIC VALUE

Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials.[ Read More ]

The intrinsic value of one OFIX stock under the base case scenario is HIDDEN Compared to the current market price of 18.1 USD, Orthofix Medical Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OFIX

image
FINANCIALS
747 M REVENUE
62.06%
-139 M OPERATING INCOME
-572.94%
-151 M NET INCOME
-666.60%
-45.8 M OPERATING CASH FLOW
-296.54%
-33.1 M INVESTING CASH FLOW
-35.04%
65.3 M FINANCING CASH FLOW
83846.15%
197 M REVENUE
-1.01%
-18.9 M OPERATING INCOME
13.05%
-27.4 M NET INCOME
18.11%
11.6 M OPERATING CASH FLOW
28.93%
-5.86 M INVESTING CASH FLOW
39.15%
-2.46 M FINANCING CASH FLOW
-1775.16%
Balance Sheet Decomposition Orthofix Medical Inc.
image
Current Assets 420 M
Cash & Short-Term Investments 37.8 M
Receivables 128 M
Other Current Assets 255 M
Non-Current Assets 505 M
Long-Term Investments 0
PP&E 159 M
Other Non-Current Assets 346 M
Current Liabilities 165 M
Accounts Payable 58.4 M
Short-Term Debt 5.44 M
Other Current Liabilities 101 M
Non-Current Liabilities 161 M
Long-Term Debt 129 M
Other Non-Current Liabilities 32.6 M
EFFICIENCY
Earnings Waterfall Orthofix Medical Inc.
image
Revenue 747 M
Cost Of Revenue 260 M
Gross Profit 486 M
Operating Expenses 667 M
Operating Income -139 M
Other Expenses 12.3 M
Net Income -151 M
RATIOS
65.13% GROSS MARGIN
65.13%
-18.63% OPERATING MARGIN
-18.63%
-20.28% NET MARGIN
-20.28%
-25.29% ROE
-25.29%
-16.36% ROA
-16.36%
-20.44% ROIC
-20.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Orthofix Medical Inc.
image
Net Income -151 M
Depreciation & Amortization 60.6 M
Capital Expenditures -62 M
Stock-Based Compensation 35.7 M
Change in Working Capital -54 M
Others 116 K
Free Cash Flow -108 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Orthofix Medical Inc.
image
Wall Street analysts predict an average 1-year price target for OFIX of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OFIX Lowest Price Target Wall Street Target
24 USD 32.74%
OFIX Average Price Target Wall Street Target
24 USD 32.74%
OFIX Highest Price Target Wall Street Target
24 USD 32.74%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Orthofix Medical Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 14, 2023
Bought 101 K USD
Hinrichs James F.
Director
+ 7500
13.47 USD
1 year ago
May 24, 2023
Sell 83 K USD
Kenny Kevin J.
President of Global Spine
- 4367
19 USD
1 year ago
May 26, 2023
Sell 73.6 K USD
Kenny Kevin J.
President of Global Spine
- 3876
19 USD
1 year ago
Mar 10, 2023
Sell 75.7 K USD
Maniar Shweta
Director
- 4262
17.75 USD
2 years ago
Nov 22, 2021
Bought 62.3 K USD
Paolucci Michael E
Director
+ 2000
31.15 USD
2 years ago
Nov 19, 2021
Bought 42.1 K USD
DOUG RICE
CFO
+ 1400
30.05 USD
2 years ago
Nov 19, 2021
Bought 50.2 K USD
BURZIK CATHERINE M
Director
+ 1660
30.27 USD
3 years ago
Nov 18, 2021
Bought 52 K USD
Serbousek Jon Carl
CEO
+ 1670
31.14 USD
3 years ago
Nov 18, 2021
Bought 30.3 K USD
Elting Kimberley A.
Chief Legal & Develop. Officer
+ 1000
30.34 USD
4 years ago
Jun 05, 2020
Sell 327 K USD
Finegan Michael
Chief Strategy Officer
- 8750
37.4083 USD
4 years ago
Mar 16, 2020
Bought 485 K USD
MATRICARIA RONALD A
Director
+ 20000
24.25 USD
4 years ago
Mar 12, 2020
Bought 268 K USD
Hinrichs James F.
Director
+ 10000
26.8469 USD
4 years ago
Feb 27, 2020
Bought 103 K USD
Serbousek Jon Carl
CEO
+ 2900
35.4812 USD
5 years ago
Oct 31, 2019
Bought 4.23 K USD
MATRICARIA RONALD A
Director
+ 100
42.295 USD
5 years ago
Oct 31, 2019
Bought 8.46 K USD
MATRICARIA RONALD A
Director
+ 200
42.275 USD
5 years ago
Oct 31, 2019
Bought 833 K USD
MATRICARIA RONALD A
Director
+ 19700
42.265 USD
5 years ago
Aug 28, 2019
Sell 296 K USD
Mason Brad
CEO
- 5805
50.9689 USD
5 years ago
Jun 13, 2019
Sell 294 K USD
Mason Brad
CEO
- 5767
50.9257 USD
5 years ago
Jun 13, 2019
Sell 161 K USD
Mason Brad
CEO
- 3123
51.4372 USD
5 years ago
May 14, 2019
Sell 557 K USD
Mason Brad
CEO
- 10368
53.6881 USD
5 years ago
May 14, 2019
Sell 16.3 K USD
Mason Brad
CEO
- 300
54.4133 USD
5 years ago
Apr 17, 2019
Sell 115 K USD
Mason Brad
CEO
- 2200
52.0667 USD
5 years ago
Apr 17, 2019
Sell 197 K USD
Mason Brad
CEO
- 3749
52.52 USD
5 years ago
Feb 15, 2019
Sell 13.1 K USD
Bianchi Davide
President, Global Extremities
- 201
65 USD
5 years ago
Feb 19, 2019
Sell 1.57 M USD
Bianchi Davide
President, Global Extremities
- 24199
65 USD
5 years ago
Jan 14, 2019
Sell 90.7 K USD
Mason Brad
CEO
- 1800
50.3693 USD
5 years ago
Jan 15, 2019
Sell 160 K USD
Mason Brad
CEO
- 3200
50 USD
6 years ago
Nov 05, 2018
Sell 23.9 K USD
NIEMANN BRADLEY V.
President of Global Spine
- 387
61.63 USD
6 years ago
Nov 02, 2018
Sell 219 K USD
FAULSTICK LUKE T
Director
- 3600
60.9251 USD
6 years ago
Nov 02, 2018
Sell 213 K USD
FAULSTICK LUKE T
Director
- 3500
60.9271 USD
6 years ago
Nov 02, 2018
Sell 40.1 K USD
FAULSTICK LUKE T
Director
- 650
61.7243 USD
6 years ago
Nov 02, 2018
Sell 43.2 K USD
FAULSTICK LUKE T
Director
- 700
61.7357 USD
6 years ago
Nov 02, 2018
Sell 427 K USD
Elting Kimberley A.
Chief Legal & Admin Officer
- 7000
61.0482 USD
6 years ago
Nov 02, 2018
Sell 359 K USD
DOUG RICE
CFO
- 5857
61.232 USD
6 years ago
Nov 02, 2018
Sell 12.4 K USD
DOUG RICE
CFO
- 200
61.84 USD
6 years ago
Oct 11, 2018
Sell 220 K USD
DOUG RICE
CFO
- 3949
55.648 USD
6 years ago
Sep 05, 2018
Sell 133 K USD
Mason Brad
CEO
- 2500
53.0218 USD
6 years ago
Aug 07, 2018
Sell 15.4 K USD
Mason Brad
CEO
- 300
51.41 USD
6 years ago
Aug 07, 2018
Sell 74.2 K USD
Mason Brad
CEO
- 1400
53.0179 USD
6 years ago
Aug 07, 2018
Sell 27 K USD
Mason Brad
CEO
- 500
53.954 USD
6 years ago
Aug 07, 2018
Sell 16.5 K USD
Mason Brad
CEO
- 300
55.1433 USD
6 years ago
Jul 10, 2018
Sell 147 K USD
Mason Brad
CEO
- 2500
58.6215 USD
6 years ago
Jul 03, 2018
Sell 518 K USD
NIEMANN BRADLEY V.
President of Global Spine
- 9100
56.9369 USD
6 years ago
Jul 03, 2018
Sell 123 K USD
NIEMANN BRADLEY V.
President of Global Spine
- 2150
57.3532 USD
6 years ago
Jun 20, 2018
Sell 1.69 M USD
FUJIKAWA RAYMOND
President Spine Fixation
- 28047
60.1622 USD
6 years ago
Jun 20, 2018
Sell 254 K USD
FUJIKAWA RAYMOND
President Spine Fixation
- 4196
60.494 USD
6 years ago
Jun 18, 2018
Sell 1.13 M USD
Finegan Michael
Chief Strategy Officer
- 19275
58.6341 USD
6 years ago
Jun 18, 2018
Sell 634 K USD
Finegan Michael
Chief Strategy Officer
- 10725
59.1262 USD
6 years ago
Jun 19, 2018
Sell 886 K USD
Bianchi Davide
President Extremity Fixation
- 14762
60 USD
6 years ago
Jun 14, 2018
Sell 145 K USD
Mason Brad
CEO
- 2500
57.9454 USD
6 years ago
May 03, 2018
Bought 520 K USD
MATRICARIA RONALD A
Director
+ 10000
51.9724 USD
6 years ago
Dec 11, 2017
Sell 289 K USD
NIEMANN BRADLEY V.
President Biostim
- 5547
52.0751 USD
6 years ago
Nov 28, 2017
Sell 267 K USD
Mason Brad
CEO
- 5000
53.48 USD
7 years ago
Nov 06, 2017
Sell 246 K USD
FAULSTICK LUKE T
Director
- 4800
51.2179 USD
7 years ago
Sep 11, 2017
Sell 344 K USD
NIEMANN BRADLEY V.
President Biostim
- 6956
49.4431 USD
7 years ago
Sep 11, 2017
Sell 364 K USD
DOUG RICE
CFO
- 7353
49.4613 USD
7 years ago
Aug 21, 2017
Sell 131 K USD
Mason Brad
CEO
- 2733
48.1 USD
7 years ago
Aug 10, 2017
Sell 300 K USD
FUJIKAWA RAYMOND
President Spine Fixation
- 6364
47.0619 USD
8 years ago
Nov 08, 2016
Sell 184 K USD
Mason Brad
CEO
- 5000
36.8145 USD
8 years ago
Nov 10, 2016
Sell 167 K USD
Mason Brad
CEO
- 4538
36.8432 USD
8 years ago
Sep 01, 2016
Sell 1.13 M USD
Finegan Michael
Chief Strategy Officer
- 25000
45.16 USD
8 years ago
Jun 10, 2016
Sell 193 K USD
Sainz Maria
Director
- 4157
46.329 USD
8 years ago
Jun 09, 2016
Sell 843 K USD
Mason Brad
CEO
- 18336
46 USD
8 years ago
Jun 08, 2016
Sell 152 K USD
NIEMANN BRADLEY V.
President Biostim
- 3402
44.7 USD
8 years ago
Jun 08, 2016
Sell 152 K USD
NIEMANN BRADLEY V.
President Biostim
- 3402
44.7 USD
8 years ago
May 20, 2016
Sell 580 K USD
GOODWIN ROBERT ALLEN II
President Biologics
- 13187
44 USD
8 years ago
Apr 14, 2016
Sell 2.19 M USD
Finegan Michael
Chief Strategy Officer
- 52222
42 USD
8 years ago
Apr 18, 2016
Sell 1.26 M USD
Finegan Michael
Chief Strategy Officer
- 28750
44 USD
9 years ago
Nov 11, 2015
Sell 594 K USD
Finegan Michael
Chief Strategy Officer
- 14140
42 USD
9 years ago
Nov 06, 2015
Sell 147 K USD
Schumm Jeffrey
Chief Administrative Officer
- 3643
40.2477 USD
9 years ago
Nov 06, 2015
Sell 463 K USD
Schumm Jeffrey
Chief Administrative Officer
- 11357
40.803 USD
9 years ago
Nov 06, 2015
Sell 324 K USD
Mason Brad
CEO
- 8038
40.2815 USD
9 years ago
Nov 06, 2015
Sell 286 K USD
Mason Brad
CEO
- 6980
40.9737 USD
7. News
Orthofix to Participate in Upcoming Investor Conferences LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024,. businesswire.com - 4 days ago
Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript Orthofix Medical Inc. (NASDAQ:OFIX ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Iseult McMahon - BTIG Jason Wittes - ROTH MKM Operator Good morning, and welcome to the Orthofix Third Quarter 2024 Earnings Call. I am Fran, and I'll be the operator assisting you today. seekingalpha.com - 6 days ago
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). globenewswire.com - 1 week ago
FINAL REMINDER OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Orthofix Medical Inc. Investors to Participate in the Class Action Lawsuit! NEW YORK CITY, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class"). accesswire.com - 1 week ago
OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of former SeaSpine Holdings Corporation shareholders that purchased or otherwise acquired newly issued Orthofix Medical Inc. (NASDAQ: OFIX) stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction by which Orthofix merged with and acquires SeaSpine. Orthofix is a global spine and orthopedics company that offers biologics, spinal hardware, bone growth therapies, and specialized orthopedic solutions, among other things, to healthcare professionals throughout the world. prnewswire.com - 1 week ago
Orthofix (OFIX) Q3 Earnings Surpass Estimates Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to earnings of $0.07 per share a year ago. zacks.com - 1 week ago
Orthofix Announces New Term Loan LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period. The term loan is agented by Oxford Finance LLC (“Oxford”) and provides non-dilutive capital and financial flexibility to support Orthofix's continued focus on profitable growth. The proceeds from the initial fundi. businesswire.com - 1 week ago
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of. businesswire.com - 1 week ago
FINAL OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Orthofix Medical Inc. Investors to Join the Class Action Lawsuit! NEW YORK CITY, NY / ACCESSWIRE / November 7, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class"). accesswire.com - 1 week ago
OFIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Orthofix Medical Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! NEW YORK CITY, NY / ACCESSWIRE / November 6, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class"). accesswire.com - 1 week ago
OFIX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Orthofix Medical Inc. Investors Have Opportunity to Lead Class Action Lawsuit! NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class"). accesswire.com - 1 week ago
OFIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Orthofix Medical Inc. Investors Have Opportunity to Lead Class Action Lawsuit! NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class"). accesswire.com - 1 week ago
8. Profile Summary

Orthofix Medical Inc. OFIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 691 M
Dividend Yield 0.00%
Description Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Contact 3451 Plano Parkway, Lewisville, TX, 75056 https://www.orthofix.com
IPO Date April 24, 1992
Employees 1634
Officers Mr. Massimo Calafiore President, Chief Executive Officer, Director and Interim President of Global Spine Mr. Tyler P. Lipschultz President of Global Biologics Ms. Stephanie Walsh Chief Human Resources Officer Ms. Julie D. Dewey Chief Investor Relations & Communications Officer Ms. Julie B. Andrews Chief Financial Officer Ms. Jill Mason Interim Chief Ethics & Compliance Officer and Vice President of Corporate Counsel Ms. Aviva McPherron President of Global Operations & Quality Mr. Geoffrey C. Gillespie Vice President & Corporate Controller Mr. Ehab M. Esmail Senior Vice President of Global Quality, Regulatory & Clinical Affairs Mr. J. Andres Cedron Chief Legal Officer & Corporate Secretary